Aspen strikes R3.66bn deal for its menopause treatment

Aspen Pharmacare announced it will sell the European commercialisation rights and related intellectual property for its women’s health product, Ovestin, to Ennogen Healthcare International for $220m (approximately R3.66bn at the current exchange rate of R16.62 per US Dollar).

— Bizcommunity
Read the full story on Bizcommunity

This story was written and published by Bizcommunity. Business.co.za shows its headline and teaser from the publisher’s RSS feed and links to the original.

What business people are saying

0

No comments yet. Be the first.

More in Business

All →